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AbstrACt
Objective To compare the incidence of silent cerebral 
infarction and impact on cognitive function following 
transcatheter aortic valve implantation (TAVI) with the first-
generation CoreValve (Medtronic, Minneapolis, Minnesota, 
USA) and second-generation Lotus valve (Boston Scientific, 
Natick Massachusetts, USA).
Design A prospective observational study comprising 
a 1.5 T cerebral MRI scan, performed preoperatively 
and immediately following TAVI, and neurocognitive 
assessments performed at baseline, 30 days and 1 year 
follow-up.
setting University hospitals of Leeds and Leicester, UK.
Patients 66 (80.6±8.0 years, 47% male) patients with 
high-risk severe symptomatic aortic stenosis recruited 
between April 2012 and May 2015.
Main outcome measures Incidence of new cerebral 
microinfarction and objective decline in neurocognitive 
performance.
results All underwent cerebral MRI at baseline and 
immediately following TAVI, and 49 (25 Lotus, 24 
CoreValve) completed neurocognitive assessments at 
baseline, 30 days and 1 year. There was a significantly 
greater incidence of new cerebral microinfarction observed 
following the Lotus TAVI (23 (79%) vs 22 (59%), p=0.025) 
with a greater number of new infarcts per patient (median 
3.5 (IQR 7.0) vs 2.0 (IQR 3.0), p=0.002). The mean volume 
of infarcted cerebral tissue per patient was equivalent 
following the two prostheses (p=0.166). More patients 
suffered new anterior (14 (48%) vs 2 (5%), p=0.001) 
and vertebrobasilar (15 (52%) vs 7 (19%), p=0.005) 
lesions following Lotus. Lotus was associated with a 
decline in verbal memory and psychomotor speed at 30 
days. However, performance longitudinally at 1 year was 
preserved in all neurocognitive domains.
Conclusions There was a higher incidence of silent 
cerebral microinfarction and a greater number of lesions 
per patient following Lotus compared with CoreValve. 
However, there was no objective decline in neurocognitive 
function discernible at 1 year following TAVI with either 
prosthesis.
IntrODuCtIOn  
Transcatheter aortic valve implantation 
(TAVI) is advocated by both European1 and 
US2 guidance in patients with symptom-
atic aortic stenosis (AS) deemed inoperable 
or with too high a predicted postoperative 
mortality. TAVI is cost-effective,3 significantly 
improves quality of life4 and, as recent trial 
data suggest, non-inferior to surgery in inter-
mediate-risk patients,5 potentially expanding 
its application to a broader population.
However, since the landmark Placement of 
Aortic Transcatheter Valve Trial (PARTNER) 
in 2010,6 the inherent risk of disabling 
stroke associated with TAVI has been well 
recognised. Despite 10 years of refinement 
in transcatheter technology and delivery 
techniques, stroke rates remain similar.7 
Importantly, TAVI is also associated with a 
high incidence (up to 84%) of silent cerebral 
embolism as detected by diffusion-weighted 
MRI (DW-MRI);8–10 more frequent than that 
following aortic valve surgery.11
The association of new DW-MRI lesions 
post-TAVI with cognitive decline is an issue 
strengths and limitations of this study
 ► Contemporary study comprising both a novel tran-
scatheter aortic valve implantation (TAVI) design 
technology and an established device.
 ► A two-centre study combining both diffusion-weight-
ed MRI and cognitive assessments to comprehen-
sively assess cerebral injury following TAVI.
 ► Mid-term follow-up to 1 year.
 ► Not randomised.
 ► Higher field strength MRI available for more sensi-
tive detection of cerebral embolic infarction.
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currently under intense scrutiny, as it has long been 
recognised that silent cerebral infarcts can more than 
double the risk of dementia.12 Indeed the concept of post-
operative cognitive dysfunction and its relationship with 
DW-MRI has been described following valvular surgery, 
bypass grafting and left heart catheterisation.13
The Boston Scientific Lotus valve is a novel TAVI iter-
ation that incorporates a number of features specifi-
cally designed to improve on first-generation devices.14 
As such it exhibits superior deployment success rates 
when compared with the older Medtronic CoreV-
alve.15 16 However, the key concern of silent cerebral injury 
following implantation and cognitive decline remains 
unanswered. We sought to characterise the extent of new 
silent cerebral infarction using DW-MRI, and investigate 
longitudinally cognitive function following TAVI with the 
first-generation self-expanding Medtronic CoreValve and 
the second-generation mechanically-expanded Boston 
Scientific Lotus valve.
MethODs
Patient selection
This study prospectively recruited 74 patients with severe 
degenerative aortic stenosis (AS) from two large UK 
tertiary cardiothoracic centres (Leeds and Leicester) 
who were referred for TAVI between April 2012 and May 
2015. Severe AS was classified by echocardiography as 
an aortic valve area of ≤1.0 cm2 or peak velocity >4 m/s. 
The decision for TAVI in all cases was taken by a multi-
disciplinary heart team in accordance with international 
guidance.17 Exclusion criteria included any contraindica-
tion to MRI or pre-existing severe cognitive impairment 
(a Mini-Mental State Examination (MMSE) Score <10). 
Any patient deemed to exhibit new focal neurological 
dysfunction consistent with clinical stroke post-TAVI was 
also excluded. The study complied with the Declaration 
of Helsinki and all patients provided written informed 
consent.
transcatheter aortic valve implantation
TAVI was performed using either a first-generation Core-
Valve system (Medtronic, Minneapolis, Minnesota, USA) 
or the Lotus aortic valve system (Boston Scientific Corpo-
ration, Natick, Massachusetts, USA) employing standard 
techniques as previously described for both vendors.18 19 
Multidetector CT was employed to assist annular sizing 
and assess aortic calcification prior to TAVI. Percutaneous 
femoral artery access was the default approach. Balloon 
valvuloplasty, rapid ventricular pacing and postdilatation 
(in the case of CoreValve) were employed at the discre-
tion of the operator. All patients received weight-adjusted 
unfractionated heparin to maintain an activated clotting 
time >200 s and were treated with dual antiplatelet therapy 
(aspirin 75 mg and clopidogrel 75 mg) for a minimum of 
3 months. None of the TAVI cases involved the use of a 
cerebral protection device.
neurocognitive assessment
The neurocognitive test battery was performed by trained 
assessors (medical/nursing) in a quiet comfortable 
environment at three Valve Academic Research Consor-
tium recommended time points (baseline, 30 days and 
12 months).20 Training of assessors and performance 
validation was undertaken by an experienced neuropsy-
chologist (CL). Follow-up assessment was conducted at 
the patient's home or the hospital. Total assessment time 
ranged between 60 min and 90 min with appropriate rest 
periods. Baseline characteristics, patient handedness and 
years of education were recorded. The National Adult 
Reading Test (NART) was used to calculate the full scale 
intelligent quotient (123.2−(1.029 × NART error score)). 
A broad battery of previously validated neurocogni-
tive assessments was undertaken at the designated time 
points21 and included evaluation of: cognitive reasoning: 
using MMSE, verbal memory: using the Hopkins Verbal 
Learning Test (HVLT), executive function: using the Letter 
Number Sequencing task, psychomotor speed: using the Trail 
Making Tests (TMTs) A and B, perceptual and visual memory: 
using the Digit-Symbol Substitution Test, and fine motor 
coordination and speed: using the Grooved Pegboard Test 
(Model 32025, Lafayette Instruments, Lafayette, Indiana, 
USA). Cognitive decline was defined as a reduction of the 
score by 1 SD of the baseline score for all tests.22–24
Cerebral MrI
Cerebral MRI was conducted preprocedure and postpro-
cedure (within 7 days) using identical imaging protocols. 
MRI was performed on the same 1.5 T system for all serial 
scans for any individual patient (Intera, Phillips Health-
care, Best, The Netherlands or Avanto, Siemens Medical 
Systems, Erlangen, Germany). The imaging protocol 
consisted of T2-weighted fast field echo, T2 turbo field 
echo and diffusion-weighted imaging (DWI) (22 slices, 
5 mm thick, 1 mm gap, Field of View (FOV) 350, Rect-
angular Field of View (RFOV) 100. Each scan was inde-
pendently assessed by two experienced neuroradiologists 
(AJPG, MI), blinded to all clinical/procedural details. 
Cerebral embolism or microinfarction was defined as 
a new restricted diffusion lesion on DWI. New cerebral 
microinfarcts were localised to one hemisphere and 
vascular territory. Infarct diameter was used to catego-
rise patients into small or large lesion subgroups (<5 mm 
or >5 mm; in the case of multiple lesions the largest lesion 
was used to determine status). The total infarct volume 
(mL) was measured off-line using standard postpro-
cessing software (QMass V.7.2, Medis, The Netherlands) 
as previously published.10 11
statistical analysis
Data were tested for normality using the Shapiro-Wilk 
test. Continuous variables were expressed as mean±SD or 
median (Q2–Q3 or IQR) and were tested for differ-
ences by means of a two-sided, unpaired Student's 
t-test (for comparison between groups) or a two-sided, 
paired Student's t-test (for intragroup comparison). 
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Non-parametrical testing (Mann-Whitney test) was 
performed where indicated. Categorical variables were 
given as frequencies and percentages and compared by χ2 
statistics or Fisher's exact test. The PASW software package 
(V.21.0 SPSS, IBM, Chicago, Illinois, USA) was used for 
all statistical analyses and a two-sided significance level of 
p<0.05 was considered statistically significant. The sample 
size required to detect cognitive decline (defined as a 
reduction in score by 1SD) was estimated using IBM SPSS 
sample power V.3, and using normative data for the test to 
have 80% power (α 0.05), a minimum of 17 patients was 
required in each group.
results
Patient population
A total of 66 patients (37 Medtronic CoreValve and 29 
Boston Lotus) underwent both the preoperative (median 
1 day preprocedure, IQR 14 days) and immediate post-
TAVI MRI scans (median 4 days, IQR 4 days). The baseline 
characteristics of these groups are shown in table 1. Forty-
nine of these (24 CoreValve and 25 Lotus) completed 
serial neurocognitive assessments up to 12 months. 
Reasons for non-completion were varied reflecting an 
elderly frail population (figure 1).
Patient involvement
Patients were not involved with the study design, recruit-
ment, conduct or interpretation of results obtained. 
Outcome measures were objectively measured and not 
based on patient experience.
Procedural data
TAVI was successful in all cases. Catheterisation data for the 
TAVI implant procedures are summarised in table 2. Of the 
29 Lotus implants, 7 (24%) involved device repositioning. 
Of the CoreValve implants, there were three instances of 
embolisation and the requirement of a second valve in three 
cases (two of whom were due to embolisation).
Cerebral MrI
Typical cerebral DWI images at baseline and immediately 
after TAVI are depicted in figure 2A,B, respectively.
Table 1 Patient characteristics in those with 6-month 
follow-up
Lotus 
(n=29)
CoreValve 
(n=37) P value*
Age (years) 79.8±8.9 81.2±7.2 0.459
Male, n (%) 14 (48) 17 (46) 0.851
EuroSCORE II 4.13±3.30 5.55±3.79 0.115
STS Score (%) 4.04±2.59 5.28±3.41 0.109
BMI (kg/m2) 28.5±5.2 27.2±5.4 0.323
Hypertension, n (%) 11 (38) 20 (54) 0.157
Diabetes, n (%) 5 (17) 4 (11) 0.450
Hyperlipidaemia, n (%) 17 (59) 18 (49) 0.488
Atrial fibrillation, n (%) 5 (17) 9 (24) 0.449
Previous MI, n (%) 7 (24) 2 (5) 0.026
Previous PCI, n (%) 9 (31) 10 (27) 0.774
Previous CABG, n (%) 5 (17) 8 (22) 0.618
Previous stroke, n (%) 7 (24) 6 (16) 0.454
Peripheral vascular 
disease, n (%)
4 (14) 5 (14) 0.991
eGFR (ml/min/1.73 m2) 69±19 64±17 0.342
Values are mean±SD or n (%).
*P value for comparison between procedure types.
BMI, body mass index; CABG, coronary artery bypass grafting; 
eGFR, estimated glomerular filtration rate; EuroSCORE, European 
System for Cardiac Operative Risk Evaluation; MI, myocardial 
infarction; PCI, percutaneous coronary intervention; STS, Society 
of Thoracic Surgeons. 
Figure 1 Study profile. TAVI, transcatheter aortic valve implantation. 
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Baseline: At baseline, 5 (17%) of the Lotus patients and 
10 (27%) of the CoreValve patients had evidence of pre-ex-
isting established stroke (p=0.346) with equivalent lesion 
volume (p=0.529). There was also evidence of recent micro-
infarction on cerebral DWI in two (7%) Lotus and four 
(11%) CoreValve patients (p=0.583). A greater proportion 
of patients undergoing Lotus TAVI had evidence of periven-
tricular ischaemia compared with those undergoing CoreV-
alve TAVI (19 (66%) vs 14 (38%), p=0.026).
Postprocedure:Table 3 summarises the findings of DWI 
following TAVI. There was a significantly greater incidence 
of new microinfarction observed following Lotus TAVI 
with a greater number of new infarcts per patient. These 
were predominantly of small size, with a comparable mean 
infarcted cerebral tissue volume per patient with both TAVI 
designs. More patients suffered new anterior and verte-
brobasilar lesions following Lotus than CoreValve. The 
number of new lesions following Lotus repositioning (n=7) 
and non-repositioning (n=22) did not differ (1.0 (IQR 8.0) 
vs 3.0 (IQR 3.75), p=0.438) and Lotus repositioning did not 
correlate with the number of new lesions (p=0.435). For the 
CoreValve group, the three patients in whom embolisation 
occurred had significantly greater frequency of new lesions 
postprocedure (4.0 (IQR 0.0) vs 1.0 (IQR 2.0), p=0.011), but 
no difference was seen in the three requiring a second valve 
(4.0 (IQR 0.0) vs 1.0 (IQR 2.0), p=0.148). Typical findings of 
new cerebral infarctions detected by DW-MRI post-TAVI are 
exemplified in figure 2.
baseline education and intelligence
The vast majority of patients was right-handed (CoreValve: 
21 (88%) vs Lotus: 24 (96%), p=0.234) with an equivalent 
reporting of disability on the Modified Rankin Scale (CoreV-
alve: 1.9±1.1 vs Lotus: 2.0±0.7, p=0.929). The CoreValve and 
Lotus patients were similar with respect to years of education 
(10.9±1.9 years vs 11.6±2.5 years, p=0.279) and full scale IQ 
(106±12 vs 102±15, p=0.313). Global cognition measured 
using MMSE was also equivalent (28.8±1.8 vs 28.6±1.6, 
p=0.279) with only one patient from the Lotus group indi-
cating cognitive impairment (defined as MMSE <24).25
effect of tAVI design on absolute neurocognitive function 
scores
Neurocognitive performance, prior to and following 
Lotus and CoreValve TAVI, are shown in table 4. For the 
vast majority of domains, including global cognition, 
psychomotor speed, executive function and fine motor 
Table 2 Catheterisation data for TAVI implant procedures
Lotus (n=29) CoreValve (n=37) P value*
TAVI size (n(%)) 23 mm (7 (24%))
25 mm (8 (28%))
27 mm (14 (48%))
23 mm (4 (11%))
26 mm (8 (22%))
29 mm (18 (49%))
31 mm (7 (19%))
–
Femoral route, n (%) 29 (100) 27 (73) 0.081
Sheath size (French) 18 (28%)
20 (52%)
22 (20%)
18 (100%)
Pullback PG (mm Hg) 56±27 43±19 0.023
Fluoroscopy time (min) 29±8 18±11 0.001
Procedure time (min) 159±42 143±50 0.194
Contrast (ml) 120±43 134±43 0.212
Predilatation BAV, n (%) 25 (86) 28 (77) 0.286
Postdilatation, n (%) 0 (0) 5 (14) 0.039
TAVI repositioned, n (%) 7 (24) 0 (0) 0.002
TAVI embolisation, n (%) 0 (0) 3 (8) 0.117
Need for second TAVI, n (%) 0 (0) 3 (8) 0.117
*Independent samples t-test
PG, pressure gradient; BAV, balloon aortic valvuloplasty; TAVI, transcatheter aortic valve implantation.
Figure 2 Diffusion-weighted MRI of the brain examining 
silent injury with transcatheter aortic valve implantation (TAVI). 
Cerebral images, including the brainstem and cerebellum 
before (A) and after (B) the TAVI procedure. Multiple new 
cerebral infarctions were seen, some of which are highlighted 
by the red arrows.
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coordination, no change in test scores was observed at 30 
days or 12 months following TAVI, with either the Lotus 
or CoreValve prostheses.
HVLT was used to test mnemonic function and verbal 
memory, and total learning scores remained unchanged 
over time for both CoreValve and Lotus. However, delayed 
recall scores and discrimination index were significantly 
lower at 30 days following Lotus (table 4), with 12-month 
scores returning to baseline level (delayed recall: 7.6±3.0 
vs 9.0±6.7, p=0.320, discrimination index: 10.2±1.5 vs 
10.1±2.4, p=0.867), with no change observed following 
CoreValve.
TMT assesses executive function and psychomotor 
speed, with TMT A preceding the more challenging 
Table 3 Comparison of MRI DWI following Boston Lotus and Medtronic CoreValve
Lotus (n=29) CoreValve (n=37) P value
Incidence of new microinfarction (n(%)) 23(79) 22(59) 0.025
Number of new microinfarcts per patient 3.5 (IQR 7.0) 2.0 (IQR 3.0) 0.002
Mean microinfarct volume per patient (ml) 0.36 (IQR 0.57) 0.17 (IQR 0.21) 0.166
Number of new small lesions (<5 mm) (n(%)) 124(78) 41(72) 0.005
Number of new large lesions (≥5 mm) (n(%)) 34(22) 16(28) 0.036
Number of patients with new ACA lesions (n(%)) 14(48) 2 (5) 0.001
Number of patients with new MCA lesions (n(%)) 20(69) 19(51) 0.149
Number of patients with new PCA lesions (n(%)) 10(34) 6 (16) 0.086
Number of patients with new VBA lesions (n(%)) 15(52) 7 (19) 0.005
ACA, anterior cerebral artery; DWI, diffusion-weighted imaging; MCA, middle cerebral artery; PCA, posterior cerebral artery; VBA, 
vertebrobasilar artery
Statistically significant P values < 0.05 are shown in bold. 
Table 4 Summary of neurocognitive test scores at baseline, 30 days and 12 months
TAVI Baseline 30 days P value* 12 months P value†
MMSE Lotus
CoreValve
28.6±1.6
28.8±1.8
28.8±1.8
28.4±2.0
0.468
0.251
28.7±2.0
27.9±2.8
0.743
0.277
HVLT
Total learning Lotus 21.4±7.2 21.5±4.1 0.913 23.3±6.1 0.104
CoreValve 17.7±6.3 18.6±6.1 0.512 18.3±7.8 0.764
Delayed recall Lotus 7.6±3.0 6.3±3.4 0.038 9.0±6.7 0.028
CoreValve 5.8±2.8 5.3±3.8 0.296 4.3±4.4 0.419
Discrimination Index Lotus 10.2±1.5 8.6±2.9 0.015 10.1±2.4 0.010
CoreValve 9.6±2.1 9.1±3.4 0.373 7.9±4.5 0.147
Trail Making Tests
A Lotus 47.0±15.0 56.0±27.6 0.112 50.5±19.7 0.354
CoreValve 56.9±27.8 61.1±40.0 0.566 66.1±49.8 0.431
B Lotus 170.9±86.5 140.7±62.8 0.006 152.3±87.5 0.273
CoreValve 171.1±121.4 155.2±79.0 0.548 143.3±64.4 0.969
DSST Lotus 43.2±15.8 45.5±16.0 0.254 44.2±13.5 0.253
CoreValve 33.9±14.1 34.6±13.3 0.704 34.4±15.7 0.633
LNS Lotus
CoreValve
7.6±4.5
8.3±5.1
8.6±3.5
8.8±4.2
0.387
0.662
8.6±2.6
7.9±4.8
0.876
0.291
Grooved pegboard
Dominant score Lotus
CoreValve
163.1±102.4
157.3±57.2
136.9±75.7
132.1±81.3
0.336
0.162
142.7±38.0
169.0±60.4
0.670
0.110
Non-dominant score Lotus
CoreValve
158.0±37.7
180.9±58.2
148.5±53.4
173.9±104.2
0.373
0.654
159.6±47.0
215.9±124.4
0.658
0.004
Mean±SD.
*Comparing values at baseline and 30 days, same TAVI design, paired samples t-test.
†Comparing values at 30 days and 12 months, same TAVI design, paired samples t-test.
DSST, Digit-Symbol Substitution Test; HVLT, Hopkins Verbal Learning Test; LNS, Letter Number Sequencing; MMSE, Mini-Mental State 
Examination; TAVI, transcatheter aortic valve implantation.
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TMT B. TMT B scores were significantly lower at 30 days 
following Lotus (table 4), with 12-month scores again 
returning to the baseline level (170.9±86.5 vs 152.3±87.5, 
p=0.215), and no change observed following CoreValve at 
any time point.
Presence or absence of DW-MrI lesions
At the 1-year follow-up, for each TAVI prosthesis we sought 
to compare individuals with and without DW-MRI lesions 
with respect to neurocognitive performance (table 5). Of 
the 25 Lotus patients that completed 12-month assess-
ments, 19 (76%) exhibited new DW-MRI lesions post-
TAVI, and of the 24 CoreValve patients, 13 (54%) were 
DW-MRI positive (p=0.140). Lotus patients with DW-MRI 
lesions exhibited an overall decline in global cognition 
(MMSE) at 12 months compared with those without 
(figure 3A,B). CoreValve patients with DW-MRI lesions 
had a significantly lower HVLT discrimination index at 
12 months compared with those without (figure 3C,D). 
Table 5 Within-group comparison of mean change in cognitive domain over 12 months in patients with and without diffusion-
weighted (DW) MRI lesions
Boston Lotus (n=25) Medtronic CoreValve (n=24)
DWI −ve (n=6) DWI +ve (n=19) P value DWI –ve (n=11) DWI +ve (n=13) P value
MMSE 1.2±0.8 −0.4±1.9 0.025 −0.9±2.5 −0.7±2.6 0.840
HVLT learning 4.2±5.2 1.2±7.3 0.454 1.1±3.9 1.0±9.1 0.691
HVLT delayed 6.3±12.9 −0.1±3.3 0.177 −0.2±2.5 −1.1±3.1 0.456
HVLT discrimination 0.0±1.5 −0.1±2.6 0.733 0.8±2.3 −2.3±3.5 0.019
TMT A 15.5±20.8 −0.1±15.3 0.059 18.9±64.9 5.0±14.7 0.562
TMT B −13.0±88.9 −18.3±61.4 0.870 19.6±61.6 −1.4±64.4 0.454
DSST 4.0±10.0 −0.4±9.8 0.346 −0.1±6.7 5.0±13.7 0.370
LNS 2.4±3.0 0.7±5.1 0.534 −0.5±5.0 0.8±3.6 0.474
GPBT dominant −8.2±31.5 −24.5±108.0 0.721 0.5±37.6 22.6±37.7 0.186
GPBT non-dominant −26.0±83.7 −3.2±51.3 0.914 43.0±81.3 20.8±66.8 0.235
Mean±SD.
DSST, Digit-Symbol Substitution Test; DWI, diffusion-weighted imaging; GPBT, Grooved Pegboard Test; HVLT, Hopkins Verbal Learning Test; 
LNS, Letter Number Sequencing; MMSE, Mini-Mental State Examination; TMT, Trail Making Test.
Figure 3 Line graph depicting change in Mini-Mental State Examination (MMSE) (A and B) and Hopkins Verbal Learning Test 
(HVLT) Discrimination Index (C and D) over time following Lotus and CoreValve. (Red lines indicate patients with diffusion-
weighted (DW) MRI microinfarcts, blue lines those without).
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For all of the remaining neurocognitive domains, no 
difference in performance at 1 year was noted between 
patients with and without DW-MRI lesions for either TAVI 
prosthesis.
DIsCussIOn
This two-centre study is the first to use DW-MRI and 
cognitive assessments to comprehensively compare two 
first-generation and second-generation TAVI devices. 
This study provides several new insights: (1) There was a 
high occurrence of silent cerebral embolism during TAVI 
affecting both first-generation and second-generation 
prosthesis designs (with 66% of the total study popula-
tion exhibiting new DW-MRI lesions post-TAVI). (2) The 
Lotus valve exhibited a significantly higher incidence of 
new DW-MRI microinfarcts, with more than twice the 
number of lesions per patient than observed following 
CoreValve. (3) DW-MRI lesions are of similar size, but 
more frequently observed in the anterior cerebral and 
vertebrobasilar territories following Lotus compared with 
CoreValve. (4) Despite a higher DW-MRI burden and an 
initial deterioration in verbal memory following Lotus, 
TAVI does not appear detrimental to mid-term neuro-
cognitive function, with 12-month scores in all domains 
being equivalent to baseline following both Lotus and 
CoreValve. (5) For the majority of domains, including 
executive function, psychomotor speed, perceptual and 
visual memory, and fine motor coordination and speed, 
the presence of DW-MRI lesions did not influence neuro-
cognitive function at 1 year for either valve. This latter 
point is consistent with previous work that demonstrated 
preserved 2-year cognitive performance in an unselected 
TAVI population, irrespective of DW-MRI status.23
Cognitive decline after cardiac surgery is associated 
with increased morbidity and mortality26 and has signif-
icant social and economic implications.23 TAVI has revo-
lutionised the management of high-risk patients with 
symptomatic aortic stenosis worldwide. However, deter-
mining whether the high incidence of silent DW-MRI 
lesions seen post-TAVI predisposes to cognitive decline, 
and whether TAVI design has any impact on this, remains 
a crucial prerequisite to its more widespread use. Despite 
its advanced design, our study suggests that the use of 
the second-generation Lotus valve carries a higher risk 
of silent cerebral infarction, but without an objectively 
discernible decline in neurocognitive function at 1 year, 
comparable to the CoreValve prosthesis.
The multiple and diffusely distributed silent cere-
bral lesions detected by DW-MRI post-TAVI are in 
keeping with an embolic aetiology. We have previously 
shown severity of aortic arch atheroma is an indepen-
dent risk factor for the development of new cerebral 
infarcts following TAVI.10 Transcranial Doppler studies, 
performed during TAVI, have indicated balloon valvu-
loplasty, prosthesis positioning and implantation 
as particular moments for cerebral embolisation,27 
suggesting that manipulation of the native aortic valve 
is also an important source.
Oversizing has been associated with tissue embo-
lisation on histopathological analysis28 and is recom-
mended to a degree with first-generation designs 
in order to prevent paravalvular regurgitation. The 
higher cover index and greater displacement forces 
on degenerate native leaflets might consequently 
be expected to precipitate a greater degree of tissue 
dehiscence and embolisation. Balloon postdilatation 
has also been demonstrated to significantly predict 
acute neurological events.7 Despite the larger valve 
size, greater frequency of valve embolisation and 
use of postdilatation, new DW-MRI lesions were less 
frequently seen following CoreValve. The Lotus valve is 
fully repositionable, reflecting the longer fluoroscopy 
times observed with this prosthesis. However, our data 
suggest that repositioning per se was not a significant 
contributor to the frequency of new DW-MRI lesions 
observed. The Lotus delivery system typically requires 
20F or wider sheaths, and thus greater endothelial 
disruption during manipulation around the aortic 
arch may underlie the higher incidence of cerebral 
microinfarction seen after Lotus TAVI. Future studies 
are required to determine whether these findings may 
translate into variation in the incidence of clinical 
stroke.
We and others have previously demonstrated 
that majority of DW-MRI lesions immediately post-TAVI 
appear to resolve by 6 months.11 However, this resolution 
does not necessarily indicate tissue normalisation. The 
insensitivity of lower field strength imaging has been 
suggested as one explanation.13 Furthermore, rat models 
of cerebral ischaemic insult confirm histological neuronal 
damage despite DW-MRI resolution, cautioning the use 
of imaging alone to assess ischaemic injury.29 We there-
fore sought to compliment cerebral MRI with a battery of 
well-validated neurocognitive assessment tools.
There is a large body of evidence to indicate that 
silent cerebral injury heralds adverse cognitive conse-
quences. They are associated with an increased risk of 
mild cognitive impairment,30 and may double the risk 
of dementia (most commonly Alzheimer’s disease), 
with a steeper rate of cognitive decline observed the 
greater the number of infarctions.12 It is feasible that 
the decline in verbal memory seen at 30 days following 
Lotus, which was not observed following CoreValve, is a 
reflection of the associated higher burden of DW-MRI 
lesions.
To date, few studies have combined DW-MRI and 
cognitive assessment following TAVI with CoreValve or 
Edwards-Sapien. The largest involved 111 subjects23 with 
the other three averaging 40 patients.8 22 31 No decline 
in any cognitive domain was observed despite the occur-
rence of diffuse microinfarcts affecting both cerebral 
hemispheres,22 and patients with and without DW-MRI 
lesions performed equally well.23 These findings are 
consistent with our study. Our observed high incidence 
of new DW-MRI lesions post-TAVI appeared to lack clin-
ical sequelae when cognition was objectively assessed at 
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12 months, and this was the case following both first-gen-
eration and second-generation devices.
This study is noteworthy in the context of contempo-
rary TAVI trials. Results from the PARTNER 2 Trial have 
suggested that transfemoral TAVI results in a lower rate 
of death or disabling stroke in intermediate-risk patients, 
with an average age similar to this study of 81.5 years, 
when compared with surgery.32 Younger patients would 
expectedly exhibit lower burdens of aortic atheroma and 
thus fewer silent DW-MRI lesions, irrespective of TAVI 
design. In the recent Claret Embolic Protection and TAVI 
(CLEAN-TAVI)33 and SENTINEL34 trials, cerebral protec-
tion reduced new ischaemic cerebral lesions. However, 
Lotus patients were notably absent from both studies. 
While pre-existing lesion volume predicted future cere-
bral lesion volume,34 the baseline and post-TAVR volume 
of established DWI lesions in our study of both CoreValve 
and Lotus were equivalent. Our work suggests that devices 
to reduce lesion frequency may be a particularly pertinent 
adjunct to Lotus TAVI and potentially offset the decline 
in verbal memory and psychomotor speed we observed 
at 30 days.
While our work indicates DW-MRI lesions do not seem 
to affect mid-term neurocognitive function, caution 
is required not to dismiss DW-MRI lesions as entirely 
innocuous, particularly given even small lesions tripled 
the risk of stroke-related death in healthy subjects aged 
50–73 years over 14 years of follow-up.35 Longer follow-up 
is required to clinically appreciate the natural history of 
cerebral injury incurred during TAVI.
limitations
Patients were not randomised to CoreValve or Lotus and 
hence the study is vulnerable to selection bias. Further-
more, we have not directly compared cognitive perfor-
mance from our two TAVI groups with that of healthy 
octogenarians, or patients managed conservatively.
There was attrition in patients completing the study 
protocol, with 5 patients failing to complete postinter-
vention imaging and 17 patients with imaging data failing 
to complete 12-month neurocognitive assessments. Four-
teen patients (19%) withdrew from the study and this was 
often due to deteriorating health or transfer into long-
term nursing care There is hence an inherent risk of bias 
as potentially those with most marked decline in cognitive 
function might have been excluded. Furthermore, our 
finally analysed patient group sizes confer limited power 
to report ‘no difference’ in baseline variables raising the 
possibility of type 1  and type 2 errors, and transfer bias 
influencing our final group comparisons.
The CoreValve has been clinically in use for much 
longer than the Lotus valve. Therefore, the greater 
degree of new DWI lesions seen in the Lotus group may 
partly reflect an operator ‘learning curve’ during which 
experience and fluency in use of Lotus delivery equip-
ment was refined.
Presently, there is no internationally accepted defini-
tion of cognitive decline following cardiac procedures, 
with the potential for variation between studies. We have 
used a comprehensive battery of validated tests that cover 
a wide variety of important higher neurocognitive facul-
ties, but these may potentially be insensitive to change 
and lack validation in the context of TAVI.
Patients in atrial fibrillation on formal anticoagulation 
had their warfarin withheld prior to their TAVI proce-
dure, with full dose heparin during the TAVI implant 
and recommencement of warfarin on the evening of the 
procedure. However, it is not possible to exclude cardiac 
thrombus associated with atrial fibrillation as a potential 
contributor to microinfarction.
Our work employed 1.5 T field strength imaging, which 
is the case for the majority of similar published studies. 
However, the use of higher field strengths may have 
increased detection of microinfarction and characterise 
more accurately the burden associated with different 
TAVI devices.
COnClusIOn
There was a higher incidence of silent microinfarction 
with a greater number of lesions per patient following 
second-generation Lotus compared with the first-gen-
eration CoreValve implantation. However, there was no 
objective decline in neurocognitive function discernible 
at 1 year following TAVI with either prosthesis.
Author affiliations
1Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical 
Imaging, Leeds Institute for Cardiovascular and Metabolic Medicine, University of 
Leeds, Leeds, UK
2Cognitive Science Research Unit, University of Westminster, London, UK
3Interventional Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds General 
Infirmary, Leeds, UK
4Department of Cardiovascular Sciences, BHF Cardiovascular Research Centre, 
University of Leicester, Leicester, UK
5National Institute of Health Research (NIHR) Cardiovascular Biomedical Research 
Unit, Glenfield Hospital, Leicester, UK
Contributors JPG conceived and designed the study. TAM drafted the manuscript. 
CL compiled the comprehensive battery of neurocognitive tests and instructed on 
their correct implementation. FR, TAM, AU, LED and AS performed the recruitment 
of patients and their neurocognitive assessment. GPM supervised and AS oversaw 
the University of Leicester contribution. MI and AJPG performed MRI image 
analysis. DJB and CM carried out TAVI implantation. TAM and AU analysed data 
and interpreted the results. PPS and PG gave input into data interpretation. PPS, 
PG, JRJF, GJF, SP and GPM were involved in critical and intellectual revision of the 
article. All authors edited and revised the manuscript. All authors read and approved 
the final manuscript. 
Funding This study was part-funded by the British Heart Foundation 
(PG/11/126/29321), an investigator research grant from Boston Scientific and also 
the National Institute for Health Research (NIHR) Leeds Clinical Research Facility.
Competing interests DJB and CM are consultants and proctors for both Medtronic 
and Boston Scientific. JPG and SP have received an educational research grant 
from Philips Healthcare. 
Patient consent for publication Not required.
ethics approval National Research Ethics Service (08/H1307/106). 
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All clinically important data from this observational study 
have been reported on in the manuscript.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
 o
n
 9 April 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022329 on 21 January 2019. Downloaded from 
9Musa TA, et al. BMJ Open 2019;9:e022329. doi:10.1136/bmjopen-2018-022329
Open access
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
reFerenCes
 1. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the 
management of valvular heart disease (version 2012). Eur Heart J 
2012;33:2451–96.
 2. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline 
for the management of patients with valvular heart disease: executive 
summary: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines. J Am Coll 
Cardiol 2014;63:2438–88.
 3. Fairbairn TA, Meads DM, Hulme C, et al. The cost-effectiveness of 
transcatheter aortic valve implantation versus surgical aortic valve 
replacement in patients with severe aortic stenosis at high operative 
risk. Heart 2013;99:914–20.
 4. Fairbairn TA, Meads DM, Mather AN, et al. Serial change in health-
related quality of life over 1 year after transcatheter aortic valve 
implantation: predictors of health outcomes. J Am Coll Cardiol 
2012;59:1672–80.
 5. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical 
Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J 
Med Overseas Ed 2016;374:1609–20.
 6. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve 
implantation for aortic stenosis in patients who cannot undergo 
surgery. N Engl J Med 2010;363:1597–607.
 7. Fearon WF, Kodali S, Doshi D, et al. Outcomes after transfemoral 
transcatheter aortic valve replacement: a comparison of the 
randomized PARTNER (Placement of AoRTic TraNscathetER Valves) 
trial with the NRCA (Nonrandomized Continued Access) registry. 
JACC Cardiovasc Interv 2014;7:1245–51.
 8. Kahlert P, Knipp SC, Schlamann M, et al. Silent and apparent 
cerebral ischemia after percutaneous transfemoral aortic valve 
implantation: a diffusion-weighted magnetic resonance imaging 
study. Circulation 2010;121:870–8.
 9. Ghanem A, Müller A, Nähle CP, et al. Risk and fate of cerebral 
embolism after transfemoral aortic valve implantation: a prospective 
pilot study with diffusion-weighted magnetic resonance imaging. J 
Am Coll Cardiol 2010;55:1427–32.
 10. Fairbairn TA, Mather AN, Bijsterveld P, et al. Diffusion-weighted MRI 
determined cerebral embolic infarction following transcatheter aortic 
valve implantation: assessment of predictive risk factors and the 
relationship to subsequent health status. Heart 2012;98:18–23.
 11. Uddin A, Fairbairn TA, Djoukhader IK, et al. Consequence of cerebral 
embolism after transcatheter aortic valve implantation compared with 
contemporary surgical aortic valve replacement: effect on health-
related quality of life. Circ Cardiovasc Interv 2015;8:e001913.
 12. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts 
and the risk of dementia and cognitive decline. N Engl J Med 
2003;348:1215–22.
 13. Meller SM, Baumbach A, Brickman AM, et al. Clinical implications for 
diffusion-weighted MRI brain lesions associated with transcatheter 
aortic valve replacement. Catheter Cardiovasc Interv 2014;83:502–8.
 14. Meredith IT, Walters DL, Dumonteil N, et al. 1-Year outcomes with 
the fully repositionable and retrievable lotus transcatheter aortic 
replacement valve in 120 high-risk surgical patients with severe 
aortic stenosis: results of the REPRISE II Study. JACC Cardiovasc 
Interv 2016;9:376–84.
 15. Gooley RP, Talman AH, Cameron JD, et al. Comparison of self-
expanding and mechanically expanded transcatheter aortic valve 
prostheses. JACC Cardiovasc Interv 2015;8:962–71.
 16. Musa TA, Uddin A, Dobson LE, et al. Cardiovascular magnetic 
resonance assessment of 1st generation CoreValve and 2nd 
generation Lotus valves. J Interv Cardiol 2018;31:391–9.
 17. Vahanian A, Alfieri O, Al-Attar N, et al. Transcatheter valve 
implantation for patients with aortic stenosis: a position statement 
from the European Association of Cardio-Thoracic Surgery (EACTS) 
and the European Society of Cardiology (ESC), in collaboration 
with the European Association of Percutaneous Cardiovascular 
Interventions (EAPCI). Eur Heart J 2008;29:1463–70.
 18. Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day 
outcomes following transcatheter aortic valve implantation using the 
third generation (18 Fr) corevalve revalving system: results from the 
multicentre, expanded evaluation registry 1-year following CE mark 
approval. EuroIntervention 2008;4:242–9.
 19. Meredith IT, Hood KL, Haratani N, et al. Boston Scientific Lotus 
valve. EuroIntervention 2012;8(Suppl Q):Q70–Q74.
 20. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized 
endpoint definitions for transcatheter aortic valve implantation: the 
Valve Academic Research Consortium-2 consensus document. Eur 
Heart J 2012;33:2403–18.
 21. Hachinski V, Iadecola C, Petersen RC, et al. National Institute 
of Neurological Disorders and Stroke-Canadian Stroke Network 
vascular cognitive impairment harmonization standards. Stroke 
2006;37:2220–41.
 22. Knipp SC, Kahlert P, Jokisch D, et al. Cognitive function after 
transapical aortic valve implantation: a single-centre study with 
3-month follow-up. Interact Cardiovasc Thorac Surg 2013;16:116–22.
 23. Ghanem A, Kocurek J, Sinning JM, et al. Cognitive trajectory after 
transcatheter aortic valve implantation. Circ Cardiovasc Interv 
2013;6:615–24.
 24. Zamvar V, Williams D, Hall J, et al. Assessment of neurocognitive 
impairment after off-pump and on-pump techniques for coronary 
artery bypass graft surgery: prospective randomised controlled trial. 
BMJ 2002;325:1268.
 25. Crum RM, Anthony JC, Bassett SS, et al. Population-based norms 
for the Mini-Mental State Examination by age and educational level. 
JAMA 1993;269:2386–91.
 26. Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral 
outcomes after coronary bypass surgery. Multicenter Study 
of Perioperative Ischemia Research Group and the Ischemia 
Research and Education Foundation Investigators. N Engl J Med 
1996;335:1857–63.
 27. Kahlert P, Al-Rashid F, Döttger P, et al. Cerebral embolization during 
transcatheter aortic valve implantation: a transcranial Doppler study. 
Circulation 2012;126:1245–55.
 28. Van Mieghem NM, El Faquir N, Rahhab Z, et al. Incidence and 
predictors of debris embolizing to the brain during transcatheter 
aortic valve implantation. JACC Cardiovasc Interv 2015;8:718–24.
 29. Ringer TM, Neumann-Haefelin T, Sobel RA, et al. Reversal of early 
diffusion-weighted magnetic resonance imaging abnormalities 
does not necessarily reflect tissue salvage in experimental cerebral 
ischemia. Stroke 2001;32:2362–9.
 30. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of 
stroke for the 21st century: a statement for healthcare professionals 
from the American Heart Association/American Stroke Association. 
Stroke 2013;44:2064–89.
 31. Rodés-Cabau J, Dumont E, Boone RH, et al. Cerebral embolism 
following transcatheter aortic valve implantation: comparison 
of transfemoral and transapical approaches. J Am Coll Cardiol 
2011;57:18–28.
 32. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical 
aortic-valve replacement in intermediate-risk patients. N Engl J Med 
2016;374:1609–20.
 33. Haussig S, Mangner N, Dwyer MG, et al. Effect of a cerebral 
protection device on brain lesions following transcatheter aortic valve 
implantation in patients with severe aortic stenosis: the CLEAN-TAVI 
Randomized Clinical Trial. JAMA 2016;316:592–601.
 34. Kapadia SR, Kodali S, Makkar R, et al. Protection against cerebral 
embolism during transcatheter aortic valve replacement. J Am Coll 
Cardiol 2017;69:367–77.
 35. Windham BG, Deere B, Griswold ME, et al. Small brain lesions 
and incident stroke and mortality: a cohort study. Ann Intern Med 
2015;163:22–31.
 o
n
 9 April 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022329 on 21 January 2019. Downloaded from 
